Tramadol


Curated chemical-phenotype interactions from CTD
GO IDGO nameInteraction typeReference
GO:0002523 Leukocyte migration involved in inflammatory response Increases phenotype PMID:28689766; PMID:39848458; PMID:39848458
GO:0003105 Negative regulation of glomerular filtration Increases phenotype PMID:28689766
GO:0003300 Cardiac muscle hypertrophy Increases phenotype PMID:33645892
GO:0004021 L-alanine:2-oxoglutarate aminotransferase activity Increases phenotype PMID:39848458
GO:0004035 Alkaline phosphatase activity Increases phenotype PMID:39848458
GO:0004069 L-aspartate:2-oxoglutarate aminotransferase activity Increases phenotype PMID:28499616; PMID:39848458; PMID:39848458
GO:0004111 Creatine kinase activity Increases phenotype PMID:28499616
GO:0004457 Lactate dehydrogenase activity Increases phenotype PMID:28499616
GO:0004602 Glutathione peroxidase activity Decreases phenotype PMID:39848458
GO:0004784 Superoxide dismutase activity Decreases phenotype PMID:39848458
GO:0006304 Dna modification Increases phenotype PMID:39848458
GO:0006629 Lipid metabolic process Affects phenotype PMID:33645892
GO:0006641 Triglyceride metabolic process Affects phenotype PMID:33645892
GO:0006695 Cholesterol biosynthetic process Increases phenotype PMID:28689766
GO:0006754 Atp biosynthetic process Decreases phenotype PMID:27317026
GO:0006915 Apoptotic process Increases phenotype PMID:25550769
GO:0006974 Cellular response to dna damage stimulus Increases phenotype PMID:33645892
GO:0006979 Response to oxidative stress Increases phenotype PMID:31618080
GO:0007033 Vacuole organization Increases phenotype PMID:28499616
GO:0008203 Cholesterol metabolic process Affects phenotype PMID:33645892
GO:0008219 Cell death Increases phenotype PMID:27317026; PMID:28499616; PMID:28689766
GO:0016042 Lipid catabolic process Decreases phenotype PMID:28499616; PMID:28689766; PMID:33645892
GO:0016049 Cell growth Increases phenotype PMID:28499616
GO:0018158 Protein oxidation Affects phenotype PMID:28499616; PMID:33645892
GO:0019627 Urea metabolic process Affects phenotype PMID:39848458
GO:0030199 Collagen fibril organization Increases phenotype PMID:33645892
GO:0030263 Apoptotic chromosome condensation Increases phenotype PMID:39848458
GO:0030431 Sleep Increases phenotype PMID:27641627
GO:0032769 Negative regulation of monooxygenase activity Increases phenotype PMID:29100959
GO:0042415 Norepinephrine metabolic process Affects phenotype PMID:27641627
GO:0042428 Serotonin metabolic process Affects phenotype PMID:27641627
GO:0046323 Glucose import Increases phenotype PMID:27317026
GO:0046415 Urate metabolic process Affects phenotype PMID:28689766
GO:0046449 Creatinine metabolic process Affects phenotype PMID:39848458
GO:0046466 Membrane lipid catabolic process Increases phenotype PMID:31618080
GO:0051350 Negative regulation of lyase activity Increases phenotype PMID:29100959
GO:0070265 Necrotic cell death Increases phenotype PMID:39848458
GO:0070994 Detection of oxidative stress Increases phenotype PMID:39848458
GO:0090032 Negative regulation of steroid hormone biosynthetic process Increases phenotype PMID:29100959
DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.